扩血管药物联合镇静药在伴抑郁的冠心病患者中的应用效果  

Application effect of vasodilators combined with sedatives in patients with coronary heart disease with depression

作　　者：李幸洲 徐玉莲 LI Xingzhou;XU Yulian(Department of Cardiology,Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Guangdong Province,Guangzhou510800,China)

机构地区：[1]广州市中西医结合医院心内科,广东广州510800

出　　处：《中国当代医药》2022年第16期91-94,99,共5页China Modern Medicine

摘　　要：目的研究扩血管药物联合镇静药治疗冠心病(CHD)伴抑郁患者的临床效果。方法选取2020年6月至2021年9月广州市中西医结合医院的50例CHD伴抑郁患者纳入研究,使用随机数字表法将患者分为A组与B组,各25例。B组单独使用扩血管药物,A组采取扩血管药物联合镇静药治疗。比较两组患者干预后的临床效果,使用抑郁自评量表(SDS)评估两组患者的抑郁程度,采用西雅图心绞痛生活质量量表(SAQ)评估两组患者的生活质量,同时检测两组患者的左心室射血分数(LVEF)、左心室收缩末期容积指数(LVESVI)、高敏C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)指标变化情况。结果治疗前,两组患者的LVEF、LVESVI、hs-CRP、TNF-α指标比较,差异无统计学意义(P>0.05)。治疗后,两组患者的LVEF指标均高于治疗前,LVESVI、hs-CRP、TNF-α指标均低于治疗前;且A组治疗后的LVEF指标高于B组,LVESVI、hs-CRP、TNF-α指标低于B组,差异均有统计学意义(P<0.05)。治疗前,两组患者的SDS、SAQ评分比较,差异无统计学意义(P>0.05)。两组患者治疗后的SDS评分低于治疗前,SAQ评分高于治疗前;且A组治疗后的SDS评分低于B组,SAQ评分高于B组,差异有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论对于CHD伴抑郁患者,给予扩血管药物联合镇静药治疗具有良好的临床效果,可促进患者预后恢复,改善其心功能指标,下调炎症因子指标,减轻其抑郁程度,进而改善预后,提高患者生活质量,值得借鉴。Objective To study the clinical effect of vasodilators combined with sedatives in the treatment of patients with coronary heart disease(CHD)with depression patients.Methods A total of 50 CHD patients with depression treated from June 2020 to September 2021 in Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine were selected for the study.The patients were divided into group A and group B according to random number table method,with 25 cases in each group.Group B was treated with vasodilators alone,and group A was treated with vasodilators combined with sedatives.The clinical effect of the two groups after intervention were compared.The degree of depression of the two groups was evaluated by self-rating depression scale(SDS),and the quality of life of the two groups was evaluated by Seattle angina pectoris quality of life scale(SAQ).At the same time,the changes in indicators of the left ventricular ejection fraction(LVEF),left ventricular end systolic volume index(LVESVI),high-sensitivity C-reactive protein(hs-CRP)and tumor necrosis factor-α(TNF-α)were measured.Results There were no significant differences in the indicators of LVEF,LVESVI,hs-CRP and TNF-αbetween the two groups before treatment(P>0.05).After treatment,the indicators of LVEF of the two groups were higher than those before treatment,the indicators of LVESVI,hs-CRP and TNF-αof the two groups were lower than those before treatment,the indicators of LVEF in group A after treatment was higher than that in group B,the indicators of LVESVI,hs-CRP and TNF-αin group A after treatment were lower than those in group B,and the differences were statistically significant(P<0.05).There were no significant differences in the scores of SDS and SAQ between the two groups before treatment(P>0.05).The SDS scores of the two groups after treatment were lower than those before treatment,and the SAQ scores of the two groups after treatment were higher than those before treatment,the SDS score of group A after treatment was lower than that of grou

关 键 词：扩血管药物 镇静药 冠心病 抑郁 尼可地尔 阿普唑仑 

分 类 号：R543.31[医药卫生—心血管疾病]